Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Aurinia Pharmaceuticals I...

    NASDAQ: AUPH · Real-Time Price · USD
    8.47
    -0.17 (-1.97%)
    At close: Jun 30, 2025, 3:59 PM
    8.47
    -0.06%
    After-hours: Jun 30, 2025, 05:34 PM EDT
    -1.97%
    Bid 8.28
    Market Cap 1.15B
    Revenue (ttm) 247.29M
    Net Income (ttm) 39.84M
    EPS (ttm) 0.27
    PE Ratio (ttm) 31.39
    Forward PE 11.34
    Analyst Buy
    Ask 8.61
    Volume 1,795,494
    Avg. Volume (20D) 1,328,225
    Open 8.62
    Previous Close 8.64
    Day's Range 8.43 - 8.86
    52-Week Range 5.20 - 10.67
    Beta 1.16

    About AUPH

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol AUPH
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for AUPH stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Aurinia Pharmaceuticals Inc. is scheduled to release its earnings on Jul 31, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    7 months ago
    +10.9%
    Aurinia Pharmaceuticals shares are trading higher ... Unlock content with Pro Subscription
    9 months ago
    +0.77%
    Aurinia Pharmaceuticals shares are trading higher after the company announced a board restructuring consisting of seven members.
    news image

    1 day ago · https://www.marketscreener.com

    Aurinia Pharmaceuticals Inc. - Special Call

    Presentation Operator MessageOperator (Operator)Good morning, and welcome to Aurinia's Aritinercept Phase I Study Results Conference Call. [Operator Instructions]

    news image

    1 day ago · businesswire.com

    Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)

    ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200).

    news image

    2 days ago · businesswire.com

    Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025

    ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025.

    news image

    4 days ago · zacks.com

    Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains?

    Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

    news image

    5 days ago · proactiveinvestors.com

    Aurinia shares rise ahead of key autoimmune therapy data

    Shares of Aurinia Pharmaceuticals (TSX:AUP)(NASDAQ:AUPH) jumped 6.8% to $8.57 on Thursday afternoon as investors looked ahead to the company's first clinical data update for its experimental autoimmun...

    news image

    1 month ago · zacks.com

    Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?

    Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.

    news image

    1 month ago · businesswire.com

    New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis

    ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis.

    news image

    1 month ago · benzinga.com

    Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance

    Aurinia Pharmaceuticals Inc.  AUPH reported first-quarter earnings of 16 cents per share, compared to a loss of 7 cents a year ago. This beat the consensus of 10 cents.

    news image

    1 month ago · seekingalpha.com

    Aurinia Pharmaceuticals Inc. (AUPH) Q1 2025 Earnings Call Transcript

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q1 2025 Earnings Conference Call May 12, 2025 8:30 AM ET Company Participants Andrea Christopher - Corporate Communications and IR Peter Greenleaf - Preside...

    news image

    1 month ago · zacks.com

    Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates

    Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.03 per share a year ago.

    Add to Watchlist